← All trials
NCT05193578
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 12, 2022
- Primary completion
- Jan 31, 2024
- Completion date
- Sep 30, 2024
- First posted
- Jan 18, 2022
- Last posted
- Jan 18, 2022
- Enrollment
- 154
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Southern DenmarkLead sponsor
- Odense University HospitalCollaborator
- University of Southern DenmarkOverall official - principal investigator
- University of Southern DenmarkSponsor investigator
- Region of Southern DenmarkCollaborator
- Region ZealandCollaborator
- Steno Diabetes Center CopenhagenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.